300255.SHE Hebei Changshan Biochem Pharma
- Market cap
- CNY 17.5B
- P/E
- -
- P/B
- 15.03x
- ROE
- -4.3%
- Dividend yield
- 0.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300255.SHE undervalued?
Graham numberThe Graham number of Hebei Changshan Biochem Pharma cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hebei Changshan Biochem Pharma fundamental analysis
No fundamental analysis for Hebei Changshan Biochem Pharma yet.
Hebei Changshan Biochem Pharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrat…
Full company profileHebei Changshan Biochem Pharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hebei Changshan Biochem Pharma annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.12B | 1.42B | 1.65B | 2.07B | 2.36B | 2.97B | 2.34B | 1.41B | 1.03B | 875M | 982M |
| Gross Profit | 724M | 930M | 1.18B | 1.51B | 1.62B | 1.72B | 1.02B | -323M | 93.5M | 132M | 221M |
| Operating Income | 198M | 236M | 173M | 262M | 309M | 262M | 20.5M | -1.23B | -254M | -92.8M | 53.4M |
| EBITDA | 263M | 304M | 326M | 357M | 424M | 380M | 165M | -1.07B | -107M | -189M | 50.3M |
| Net Income | 175M | 197M | 140M | 225M | 253M | 234M | 17.5M | -1.24B | -249M | -358M | -50.5M |
| EPS | 0.20 | 0.21 | 0.15 | 0.24 | 0.28 | 0.25 | 0.02 | -1.35 | -0.27 | -0.39 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 3.13B | 3.53B | 3.84B | 3.94B | 4.57B | 5.19B | 6.04B | 4.60B | 4.52B | 4.35B | 4.30B |
| Total Liabilities | 843M | 1.09B | 1.32B | 1.22B | 1.72B | 2.12B | 2.98B | 2.80B | 2.99B | 3.18B | 3.17B |
| Shareholders' Equity | 2.23B | 2.37B | 2.51B | 2.71B | 2.85B | 3.07B | 3.06B | 1.81B | 1.56B | 1.20B | 1.17B |
| Cash & Short-term Investments | 1.04B | 1.05B | 1.02B | 563M | 481M | 543M | 798M | 231M | 236M | 128M | 72.1M |
| Total Debt | 609M | 732M | 953M | 618M | 1.29B | 1.56B | 2.10B | 1.74B | 1.55B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 172M | 162M | 293M | -58.1M | -184M | 2.87M | 3.13M | 33.7M | 56.2M | 55.7M | - |
| Capital Expenditure | 96.5M | 158M | 235M | 163M | 200M | 308M | 431M | 239M | 240M | 123M | 106M |
| Free Cash Flow | 75.4M | 3.98M | 58.0M | -222M | -383M | -305M | -428M | -206M | -183M | -67.7M | -52.2M |
| Ratios | |||||||||||
| ROE | 7.9% | 8.3% | 5.6% | 8.3% | 8.9% | 7.6% | 0.6% | -68.5% | -16.0% | -29.7% | -4.3% |
| ROA | 5.6% | 5.6% | 3.6% | 5.7% | 5.5% | 4.5% | 0.3% | -27.0% | -5.5% | -8.2% | -1.2% |
| Net Profit Margin | 15.7% | 13.9% | 8.5% | 10.9% | 10.7% | 7.9% | 0.7% | -87.9% | -24.2% | -40.9% | -5.1% |
| Debt to Equity | 0.27x | 0.31x | 0.38x | 0.23x | 0.45x | 0.51x | 0.69x | 0.96x | 0.99x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hebei Changshan Biochem Pharma dividends
- Dividend yield
- 0.68%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 27, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 119M | 0.13 | - |
| 2024 | CNY 120M | 0.13 | - |
| 2023 | CNY 108M | 0.12 | - |
| 2022 | CNY 124M | 0.13 | 708.0% |
| 2021 | CNY 61.9M | 0.07 | 26.5% |
| 2020 | CNY 12.2M | 0.01 | 4.8% |
| 2019 | CNY 26.2M | 0.03 | 11.6% |
| 2018 | CNY 61.4M | 0.07 | 43.9% |
| 2017 | CNY 47.7M | 0.05 | 24.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 18:10 on Apr 20, 2016.
Who owns Hebei Changshan Biochem Pharma
- Insiders 36.05%
- Institutions 1.70%
- Public & others 62.26%
- Shares outstanding 919M
- Free float 595M
Hebei Changshan Biochem Pharma company profile
- Company name
- Hebei Changshan Biochem Pharma
- Ticker
- 300255.SHE
- ISIN
- CNE1000016C2
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 19, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,194
- Fiscal year end
- December
- Address
- No. 71 Menglong Street, South Zone, Shijiazhuang, China, 050800
- Phone
- 86 311 8919 0181
- Website
- hbcsbio.com
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services. It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.
Hebei Changshan Biochem Pharma management
10- Mr. Xiaodong GaoChairman of the Board & GM · born 1973
- Ms. Xiaohua YueDeputy GM & CFO · born 1971
- Ms. Yunxia SunDeputy GM & Non-Independent Director · born 1981
- Mr. Zhenggang QieDeputy GM & Non-Independent Director · born 1971
- Mr. Zhongying LiuDeputy GM & Secretary · born 1977
- Ms. Qing ZhangDeputy General Manager · born 1974
- Mr. Xnjun ZhangDeputy General Manager · born 1983
- Mr. Zhang TaoDeputy General Manager · born 1978
- Ms. Guohong AnDeputy General Manager · born 1968
- Mr. Yanlu ChangDeputy General Manager · born 1983